Immunosuppressed Hamster Model for Adenovirus Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective animal models for replicating human adenoviruses, which hinders the development of anti-adenovirus drugs, especially for immunocompromised patients, due to the species-specific nature of human adenoviruses and their poor replication in non-immunosuppressed animals.
Innovation Solution
The use of immunosuppressed small mammals, such as hamsters, to create a model for evaluating anti-adenovirus agents by administering human adenovirus vectors and monitoring virus replication and organ involvement, allowing for the assessment of drug efficacy and toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human adenovirus vectors are administered to non-immunosuppressed animals, then the species-specific nature prevents effective replication, but administering to immunosuppressed animals enables replication while introducing immune system complications
Solution Approach 1:
The patent changes the immune status parameter of the animal model from immunocompetent to immunosuppressed, enabling human adenovirus replication in small mammals. This parameter change allows the virus to replicate effectively while acknowledging the necessary immune suppression condition through cyclophosphamide treatment
2Productivity
If no animal model is used, then drug screening cannot be performed, but creating an animal model requires immunosuppression which complicates the system
Solution Approach 1:
The patent uses cyclophosphamide as an intermediary substance to achieve immunosuppression, creating a controllable condition that enables virus replication and drug screening while managing the complexity through a well-established chemotherapeutic agent with known mechanisms and dosing protocols
3Measurement precision
If immunosuppressed animal models are created, then human adenovirus replication can be monitored, but the model complexity increases due to immune system manipulation
Solution Approach 1:
The patent applies preliminary immunosuppression treatment with cyclophosphamide before adenovirus administration, establishing the necessary immune-compromised state in advance. This preliminary action simplifies subsequent virus monitoring by ensuring consistent replication conditions without needing to manipulate the immune system during the actual monitoring phase
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the evaluation of anti-adenovirus drugs in a model that replicates human adenovirus infections, providing insights into drug efficacy and toxicity, mirroring the conditions of immunocompromised patients, and demonstrates the effectiveness of lipid-ester prodrugs like HDP-CDV in inhibiting adenovirus replication.
Implementation Method 1
The immune system of the small mammal is suppressed using cyclophosphamide
Implementation Method 2
Ads enter cells via receptor-mediated endocytosis and express their genes in the cell nucleus
Implementation Method 3
demonstrates the effectiveness of lipid-ester prodrugs like HDP-CDV in inhibiting adenovirus replication
Data Source
AI summary
A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents.